Policy & Regulation
Innate Pharma reports sustained efficacy of lacutamab in Sézary syndrome and mycosis fungoides
23 May 2025 - Clinical-stage biotechnology company Innate Pharma SA (Euronext Paris:IPH) (Nasdaq:IPHA) on Friday announced long-term data from its Phase 2 TELLOMAK trial, confirming durable responses ...
Genentech reports extended survival benefit with Columvi in relapsed or refractory DLBCL patients
23 May 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), on Friday reported two-year follow-up data from the Phase III STARGLO study, showing a 40% imp...
Accent Therapeutics to report on DHX9 inhibitor study at 2025 ASCO Annual Meeting
23 May 2025 - Clinical-stage biopharmaceutical company Accent Therapeutics announced on Thursday that it will present its Phase 1/2 study of the first-in-class oral DHX9 inhibitor, ATX-559, at the 202...
Novita reports positive data in advanced and metastatic solid tumours trial
23 May 2025 - Novita Pharmaceuticals Inc, a clinical-stage pharmaceutical company focused on novel cancer drugs through its proprietary fascin inhibitor technology, announced on Thursday additional re...
Eisai to present analysis of E7386, co-created with PRISM BioLab, at ASCO Annual Meeting
23 May 2025 - PRISM BioLab Co Ltd, a discovery and development biotechnology company, announced on Thursday that a combination study of E7386 and Lenvatinib mesylate codeveloped with its partner Eisai...
DualityBio and Avenzo report FDA clearance of IND application for novel EGFR/HER3 bispecific ADC AVZO-1418/DB-1418
23 May 2025 - Duality Biotherapeutics ('DualityBio') (HKEX:09606) and its partner Avenzo Therapeutics Inc, a clinical-stage biotechnology company, announced on Thursday that the US Food and ...